Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation

Brain Research

Volumn 1247, Issue , 2009, Pages 1-10

  D'Souza, Antoni ^a,b   Onem, Eylem ^a,b   Patel, Pranav ^a,b   La Gamma, Edmund F ^a,b   Nankova, Bistra B ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

Butyrate; Gene expression; Neurotransmitter; Short chain fatty acids; Tyrosine hydroxylase; Valproic acid

Indexed keywords

ADRENALIN; BUTYRIC ACID; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; MESSENGER RNA; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CATECHOLAMINERGIC SYSTEM; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE METABOLISM; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REPORTER GENE; RNA DEGRADATION; RNA STABILITY; RNA SYNTHESIS; SYMPTOM; TRANSCRIPTION INITIATION;

ANIMALS; BRAIN; CATECHOLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; NEURAL PATHWAYS; NEURONS; PC12 CELLS; PROMOTER REGIONS, GENETIC; RATS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TYROSINE 3-MONOOXYGENASE; VALPROIC ACID;

EID: 57349193484     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.09.088     Document Type: Article

References (64)

1. Aranyi T., Sarkis C., Berrard S., Sardin K., Siron V., Khalfallah O., and Mallet J. Sodium butyrate modifies the stabilizing complexes of tyrosine hydroxylase mRNA. Biochem. Biophys. Res. Commun. 359 (2007) 15-19
2. Baf M.H., Subhash M.N., Lakshmana K.M., and Rao B.S. Sodium valproate induced alterations in monoamine levels in different regions of the rat brain. Neurochem. Int. 24 (1994) 67-72
3. Biggs C.S., Pearce B.R., Fowler L.J., and Whitton P.S. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J. Neurochem. 59 (1992) 1702-1708
4. Blaheta R.A., Michaelis M., Driever P.H., and Cinatl Jr. J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 25 (2005) 383-397
5. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev., Drug Discov. 5 (2006) 769-784
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
7. Casteels K., and Mathieu C. Diabetic ketoacidosis. Rev. Endocr. Metab. Disord. 4 (2003) 159-166
8. Chen J.S., Faller D.V., and Spanjaard R.A. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?. Curr. Cancer Drug Targets 3 (2003) 219-236
9. Cummings J.H., Pomare E.W., Branch W.J., Naylor C.P., and Macfarlane G.T. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28 (1987) 1221-1227
10. Czyzyk-Krzeska M.F., Furnari B.A., Lawson E.E., and Millhorn D.E. Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells. J. Biol. Chem. 269 (1994) 760-764
11. Dong E., Agis-Balboa R.C., Simonini M.V., Grayson D.R., Costa E., and Guidotti A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12578-12583
12. Fader D., and Lewis E.J. Interaction of cyclic AMP and cell-cell contact in the control of tyrosine hydroxylase RNA. Brain Res. Mol. Brain Res. 8 (1990) 25-29
13. Finnerup N.B., Sindrup S.H., and Jensen T.S. Chronic neuropathic pain: mechanisms, drug targets and measurement. Fundam. Clin. Pharmacol. 21 (2007) 129-136
14. Fossom L.H., Sterling C.R., and Tank A.W. Regulation of tyrosine hydroxylase gene transcription rate and tyrosine hydroxylase mRNA stability by cyclic AMP and glucocorticoid. Mol. Pharmacol. 42 (1992) 898-908
15. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., and Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20 (2001) 6969-6978
16. Greene L.A., and Tischler A.S. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 73 (1976) 2424-2428
17. Hughes T.A. Regulation of gene expression by alternative untranslated regions. Trends Genet. 22 (2006) 119-122
18. Ichikawa J., and Meltzer H.Y. Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation. Eur. J. Pharmacol. 380 (1999) R1-3
19. Jeong M.R., Hashimoto R., Senatorov V.V., Fujimaki K., Ren M., Lee M.S., and Chuang D.M. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 542 (2003) 74-78
20. Johannessen C.U., and Johannessen S.I. Valproate: past, present, and future. CNS Drug Rev. 9 (2003) 199-216
21. Kanai H., Sawa A., Chen R.W., Leeds P., and Chuang D.M. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J. 4 (2004) 336-344
22. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., and Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007) 892-901
23. Langley B., Gensert J.M., Beal M.F., and Ratan R.R. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 41-50
24. Leng Y., and Chuang D.M. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26 (2006) 7502-7512
25. Leng Y., Liang M.H., Ren M., Marinova Z., Leeds P., and Chuang D.M. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J. Neurosci. 28 (2008) 2576-2588
26. Lonze B.E., and Ginty D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35 (2002) 605-623
27. MacFabe D.F., Cain D.P., Rodriguez-Capote K., Franklin A.E., Hoffman J.E., Boon F., Taylor A.R., Kavaliers M., and Ossenkopp K.P. Neurobiological effects of intraventricular propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behav. Brain Res. 176 (2007) 149-169
28. Mally P., Mishra R., Gandhi S., Decastro M.H., Nankova B.B., and Lagamma E.F. Stereospecific regulation of tyrosine hydroxylase and proenkephalin genes by short-chain fatty acids in rat PC12 cells. Pediatr. Res. 55 (2004) 847-854
29. Manji H.K., and Potter W. Monoaminergic Mechanisms in Bipolar Disorder (1997), Dekker, New York 1-40
30. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92 (2000) 1210-1216
31. Maurer J.A., and Wray S. Neuronal dopamine subpopulations maintained in hypothalamic slice explant cultures exhibit distinct tyrosine hydroxylase mRNA turnover rates. J. Neurosci. 17 (1997) 4552-4561
32. Mayr B., and Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev., Mol. Cell Biol. 2 (2001) 599-609
33. Moore S.J., Turnpenny P., Quinn A., Glover S., Lloyd D.J., Montgomery T., and Dean J.C. A clinical study of 57 children with fetal anticonvulsant syndromes. J. Med. Genet. 37 (2000) 489-497
34. Nankova B.B., Chua J., Mishra R., Kobasiuk C.D., and La Gamma E.F. Nicotinic induction of preproenkephalin and tyrosine hydroxylase gene expression in butyrate-differentiated rat PC12 cells: a model for adaptation to gut-derived environmental signals. Pediatr. Res. 53 (2003) 1-6
35. Parab S., Nankova B.B., and La Gamma E.F. Differential regulation of the tyrosine hydroxylase and enkephalin neuropeptide transmitter genes in rat PC12 cells by short chain fatty acids: Concentration-dependent effects on transcription and RNA stability. Brain Res. 1132 (2007) 42-50
36. Patel P., Nankova B.B., and LaGamma E.F. Butyrate, a gut-derived environmental signal, regulates tyrosine hydroxylase gene expression via a novel promoter element. Brain Res. Dev. Brain Res. 160 (2005) 53-62
37. Peng G.S., Li G., Tzeng N.S., Chen P.S., Chuang D.M., Hsu Y.D., Yang S., and Hong J.S. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 134 (2005) 162-169
38. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
39. Peterson G.M., and Naunton M. Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30 (2005) 417-421
40. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001) 36734-36741
41. Ren M., Leng Y., Jeong M., Leeds P.R., and Chuang D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89 (2004) 1358-1367
42. Roe D.F., Craviso G.L., and Waymire J.C. Nicotinic stimulation modulates tyrosine hydroxylase mRNA half-life and protein binding to the 3′UTR in a manner that requires transcription. Brain Res. Mol. Brain Res. 120 (2004) 91-102
43. Sands S.A., Guerra V., and Morilak D.A. Changes in tyrosine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid. Neuropsychopharmacology 22 (2000) 27-35
44. Schank J.R., Liles L.C., and Weinshenker D. Reduced anticonvulsant efficacy of valproic acid in dopamine beta-hydroxylase knockout mice. Epilepsy Res. 65 (2005) 23-31
45. Schatzberg A.F., and Schieldkrautt J.J. Recent Studies on Norepinephrine Systems in Mood Disorders (1995), Raven Press, New York 911-920
46. Schmidlin M., Lu M., Leuenberger S.A., Stoecklin G., Mallaun M., Gross B., Gherzi R., Hess D., Hemmings B.A., and Moroni C. The ARE-dependent mRNA-destabilizing activity of BRF1 is regulated by protein kinase B. EMBO J. 23 (2004) 4760-4769
47. Schneider T., Turczak J., and Przewlocki R. Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 31 (2006) 36-46
48. Schroeder F.A., Lin C.L., Crusio W.E., and Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 62 (2007) 55-64
49. Shah P., Nankova B.B., Parab S., and La Gamma E.F. Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein. Brain Res. 1107 (2006) 13-23
50. Stafstrom C.E., and Bough K.J. The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr. Neurosci. 6 (2003) 67-79
51. Stoecklin G., Colombi M., Raineri I., Leuenberger S., Mallaun M., Schmidlin M., Gross B., Lu M., Kitamura T., and Moroni C. Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover. EMBO J. 21 (2002) 4709-4718
52. Topping D.L., and Clifton P.M. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81 (2001) 1031-1064
53. Tremolizzo L., Carboni G., Ruzicka W.B., Mitchell C.P., Sugaya I., Tueting P., Sharma R., Grayson D.R., Costa E., and Guidotti A. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17095-17100
54. Tsankova N., Renthal W., Kumar A., and Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev., Neurosci. 8 (2007) 355-367
55. Vecsey C.G., Hawk J.D., Lattal K.M., Stein J.M., Fabian S.A., Attner M.A., Cabrera S.M., McDonough C.B., Brindle P.K., Abel T., and Wood M.A. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J. Neurosci. 27 (2007) 6128-6140
56. Vining E.P. The ketogenic diet. Adv. Exp. Med. Biol. 497 (2002) 225-231
57. Vyas S., Faucon Biguet N., and Mallet J. Transcriptional and post-transcriptional regulation of tyrosine hydroxylase gene by protein kinase C. EMBO J. 9 (1990) 3707-3712
58. Wedel S.A., Sparatore A., Del Soldato P., Al-Batran S.E., Atmaca A., Juengel E., Hudak L., Jonas D., and Blaheta R.A. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J. Cell. Mol. Med. (2008)
59. Wieser H.G. Comparison of valproate concentrations in human plasma, CSF and brain tissue after administration of different formulations of valproate or valpromide. Epilepsy Res. 9 (1991) 154-159
60. Williams J.A., Barreiro C.J., Nwakanma L.U., Lange M.S., Kratz L.E., Blue M.E., Berrong J., Patel N.D., Gott V.L., Troncoso J.C., Johnston M.V., and Baumgartner W.A. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery. Ann. Thorac. Surg. 81 (2006) 2235-2241 discussion 2241-2
61. Yildirim E., Zhang Z., Uz T., Chen C.Q., Manev R., and Manev H. Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neurosci. Lett. 345 (2003) 141-143
62. Young L.T., Warsh J.J., Kish S.J., Shannak K., and Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol. Psychiatry 35 (1994) 121-127
63. Zarate Jr. C.A., Singh J., and Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59 (2006) 1006-1020
64. Zhu W.G., and Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Canc. Agents 3 (2003) 187-199